• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: AGA MEDICAL CORPORATION AMPLATZER DUCT OCCLUDER (UNKNOWN); TRANSCATHETER SEPTAL OCCLUDER

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

AGA MEDICAL CORPORATION AMPLATZER DUCT OCCLUDER (UNKNOWN); TRANSCATHETER SEPTAL OCCLUDER Back to Search Results
Device Problem Biocompatibility (2886)
Patient Problem Thrombosis (2100)
Event Date 04/28/2020
Event Type  Injury  
Manufacturer Narrative
Further information regarding this event has been requested.If returned, investigation results will be provided in a subsequent submission.
 
Event Description
Reference manufacturing reference number: 2135147-2020-00241.It was reported through a research article identifying amplatzer vascular plugs and duct occluders that may be related to a complications post procedure.Details are listed in the article, titled " incidence and fate of device-related left pulmonary artery stenosis and aortic coarctation in small infants undergoing transcatheter patent ductus arteriosus closure." it was reported in the article that 44 patients underwent successful tc-pda with amplatzer vascular plug ii (30), amplatzer duct occluder ii-additional sizes(10), amplatzer duct occluder i (3)and coil-filled avpi devices (1), all via an antegrade approach from february 1, 2007 to september 1, 2018.The average age of the patients were 88 days, with an average weight of 885 grams.25 of the patients were female.The patients have the following comorbidities: genetic syndrome, necrotizing enterocolitis, retinopathy of prematurity requiring intervention, adrenal insufficiency, chronic lung disease, mechanical ventilation, and cardiac medications needed.Post procedure, the patients have the following complications: 7 of the patient had femoral arterial thromboses and all were started on lovenox therapy.
 
Manufacturer Narrative
Correction information for d2.Additional information for g4, g7, h2, h10.
 
Manufacturer Narrative
Additional information for: g4, g7 h2, h3, h6, and h10.As reported in a research article, seven patients implanted with a variety of amplatzer devices had femoral arterial thromboses.A more comprehensive assessment could not be performed as the event was non-contemporaneously reported through a literature review and no device was received for analysis.Based on the information received, the cause of the reported incident could not be conclusively determined.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
AMPLATZER DUCT OCCLUDER (UNKNOWN)
Type of Device
TRANSCATHETER SEPTAL OCCLUDER
Manufacturer (Section D)
AGA MEDICAL CORPORATION
5050 nathan lane north
plymouth MN 55442
MDR Report Key10094573
MDR Text Key193303772
Report Number2135147-2020-00240
Device Sequence Number1
Product Code MAE
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,literatur
Remedial Action Other
Type of Report Initial,Followup,Followup
Report Date 12/20/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received05/27/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Was Device Available for Evaluation? No
Was the Report Sent to FDA? No
Date Manufacturer Received11/10/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Other; Required Intervention;
Patient Age88 DA
Patient Weight1
-
-